Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The general head space of MXE is often described as particularly euphoric and clear headed in comparison to that of DXM and Ketamine.
MXE exhibits a full array of dissociative distortions and alterations in visual perception.
The visual geometry found within MXE can be described as very psychedelic when compared to that of Ketamine but not as complex as that of DXM. It does not extend beyond level 5 and can be comprehensively described as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.
At high dosages, MXE can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics.
This substance does not enhance visual stimuli; instead it tends to degrade and decrease visual aptitude in a variety of ways.
The auditory effects of MXE are common in their occurrence and exhibit a range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
MXE is considered moderately addictive with a high potential for abuse and is capable of producing psychological dependence among certain users. Multiple reports describe it as 'more-ish' with tendencies toward compulsive redosing, and cases of daily habitual use have been documented across online communities.
MXE does not appear to be physically addictive. However, when psychological dependence has developed, some withdrawal effects may occur upon sudden cessation of use.
The exact toxic dosage is unknown due to MXE's limited history of human use and lack of scientific study. At high doses or in combination with depressants, depression of heart rate and respiration poses a risk of fatal respiratory depression.
Repeated heavy use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pelvic pain, and hematuria; MXE's higher potency means smaller doses are required, potentially reducing but not eliminating this risk with chronic abuse patterns.
Acute reversible cerebellar toxicity has been documented in overdose cases, with symptoms lasting one to four days after exposure; this appears to be associated with high-dose or combined consumption rather than typical recreational use.
Animal research suggests potential harmful effects on the cardiovascular system; individuals with pre-existing cardiovascular conditions should exercise particular caution.
Methoxetamine represents a deliberate exercise in rational drug design rather than accidental discovery. The compound was conceived by an anonymous chemist who sought to create a ketamine analogue with improved therapeutic properties. Structurally, MXE incorporates features from both ketamine and…
European Council Decision (September 2014) requiring Member States to implement control measures by October 2015
Prohibited under the Suchtmittelgesetz since June 26, 2019. Possession, production, and sale are criminal offenses.
Health Canada declared MXE a controlled analogue of ketamine under Schedule I of the Controlled Drugs and Substances Act in January 2011. Possession, production, and sale are prohibited.
Reportedly controlled as an analogue of ketamine under national drug legislation.
Covered by the Executive Order on Euphoriant Substances, making possession, production, and distribution illegal.
Controlled under the Betäubungsmittelgesetz since July 2013. Manufacturing, importing, possessing, selling, or transferring without license is prohibited.
Classified as a narcotic drug effective June 26, 2016. Earlier controls from July 2012 restricted importation, production, and distribution while possession for personal use remained in a legal grey area.
Prohibited since October 2011. Possession, production, and sale are illegal under Russian narcotics legislation.
Controlled under the Narcotic Drugs Control Act (SFS 1992-860) and the Narcotic Drugs Control Ordinance (SFS 1994:1554).
Regulated under the Law on Control of Narcotics no. 2313. Unauthorized possession, production, and distribution are prohibited.
Federally scheduled on July 6, 2022 under the Controlled Substances Act. Prior to federal scheduling, multiple states enacted their own controls including Alabama (2015), Arizona (2014), Florida (2012), Indiana (2012), Louisiana (2013), Minnesota (2012), North Dakota (2012), Ohio (2012), Virginia (2012), and Utah.
Listed as a controlled substance on February 18, 2014 alongside several other novel psychoactive substances. Possession, production, and sale are illegal.
Controlled as a Category I psychotropic substance. It is illegal to sell, buy, import, export, or manufacture without authorization. China's ban on production significantly impacted global MXE availability.
Listed in the national drug control law since 2012. Possession, production, and distribution are prohibited.
Added to the list of controlled stupefiant substances on August 5, 2013. Possession, production, and distribution are illegal.
Listed in the table of controlled drugs since 2016. Possession, production, and distribution are prohibited.
Added to List I of the Opium Law in July 2015. Possession, production, transport, import, export, and sale are prohibited.
Listed as a controlled substance per Official Gazette of the Republic of Slovenia No. 62/2013.
Specifically named under Verzeichnis D of the Swiss narcotics legislation. Possession, production, and sale are illegal.
Permanently classified in February 2013 following a Temporary Class Drug Order issued in April 2012. The Advisory Council on the Misuse of Drugs recommended scheduling after reviewing emerging evidence of harm.
37 sources cited
